Tempest Therapeutics
TPST
21 hedge funds and large institutions have $2.26M invested in Tempest Therapeutics in 2025 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
24% more funds holding
Funds holding: 17 → 21 (+4)
2.79% more ownership
Funds ownership: 13.19% → 15.98% (+2.8%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
62% less capital invested
Capital invested by funds: $6.02M → $2.26M (-$3.76M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.26M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$99.4K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$81K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$43.5K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$21.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$59.3K |
| 2 |
Belvedere Trading
Chicago,
Illinois
|
-$54.7K |
| 3 |
Morgan Stanley
New York
|
-$354 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$297 |
| 5 |
Wells Fargo
San Francisco,
California
|
-$31 |
TPST Hedge Fund Activity: Q4 2025 in Review
21 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q4 2025, worth a combined $2.26M — down 62% from $6.02M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TPST positions and 2 closed out — a net gain of 4 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.26M. The largest seller was DRW Securities, cutting an estimated $59.3K.
- 21 institutional investors held Tempest Therapeutics (TPST) as of Q4 2025, up from 17 in Q3 2025.
- Funds reported $2.26M of Tempest Therapeutics stock for Q4 2025, down 62% quarter-over-quarter.
- 6 funds opened new Tempest Therapeutics positions in Q4 2025 and 2 closed out, a net change of +4 holders.
- The largest Tempest Therapeutics buyer in Q4 2025 was Sabby Management, an estimated $1.26M added.
- The largest Tempest Therapeutics seller in Q4 2025 was DRW Securities, an estimated $59.3K sold.
Based on aggregated 13F filings for Q4 2025.